PriMera Scientific Medicine and Public Health (ISSN: 2833-5627)

Case Study

Volume 2 Issue 3

Smoking Increases Triglycerides and Low Density Lipoproteins in the Plasma

Mehmet Rami Helvaci*, Yasemin Kayabasi, Ozlem Celik, Guner Dede, Abdulrazak Abyad and Lesley Pocock

March 01, 2023

View PDF

Abstract

Background: There may be some significant relationships between smoking and triglycerides and low density lipoproteins (LDL) in the plasma.

Methods: Consecutive daily smokers at least for a period of six months and age and sex-matched non-smokers were included into the study. Cases with regular alcohol consumption (one drink a day) and patients with inflammatory, infectious, or devastating disorders including eating disorders, malignancies, acute or chronic renal failure, cirrhosis, chronic obstructive pulmonary disease, hyper- or hypothyroidism, or heart failure were excluded from the study.

Results: The study included 150 smokers (99 males) and 162 non-smokers. The mean age of smokers was 45.9 years, and 66.0% of them were male. Although the mean body weight, body mass index, systolic and diastolic blood pressures, and hematocrit values were similar in both groups, triglycerides (163.3 versus 151.8 mg/dL, p<0.05) and LDL (126.1 versus 117.4 mg/dL, p<0.05) were higher in the smokers, significantly. Similarly, erythrocyte sedimentation rate (ESR) (10.8 versus 9.4 mm/h, p<0.05) and C-reactive protein (CRP) (2.5 versus 2.1 mg/L, p<0.05) values were also higher in the smokers. On the other hand, high density lipoproteins (HDL) (41.1 versus 44.0 mg/dL, p<0.05) and fasting plasma glucose (FPG) (101.9 versus 111.9 mg/dL, p<0.01) values were lower in the smokers, significantly.

Conclusion: Smoking causes a low-grade systemic inflammation on vascular endothelium terminating with an accelerated atherosclerosis-induced end-organ insufficiencies all over the body. As significant indicators of the systemic inflammation, smoking increases triglycerides and LDL, parallel to ESR and CRP, whereas decreases HDL and FPG in the body.

Keywords: Smoking, triglycerides, low density lipoproteins, high density lipoproteins, fasting plasma glucose, erythrocyte sedimentation rate, C-reactive protein

References

  1. Helvaci MR, Aydin Y and Gundogdu M. “Smoking induced atherosclerosis in cancers”. HealthMED 6.11 (2012): 3744-9.
  2. Helvaci MR., et al. “Metformin and parameters of physical health”. Intern Med 47.8 (2008): 697-703.
  3. Helvaci MR., et al. “Physical inactivity or an excessive eating habit”. Middle East J Nursing 12.1 (2018): 14-8.
  4. Eckel RH, Grundy SM and Zimmet PZ. “The metabolic syndrome”. Lancet 365.9468 (2005): 1415-28.
  5. Helvaci MR., et al. “Aging syndrome”. World Family Med 15.3 (2017): 39-42.
  6. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106.25 (2002): 3143-421.
  7. Juel K. “Life expectancy and mortality in Denmark compared to Sweden”. What is the effect of smoking and alcohol? Ugeskr Laeger 170.33 (2008): 2423-7.
  8. Helvaci MR., et al. “The most desired values of high and low density lipoproteins and triglycerides in the plasma”. World Family Med 18.8 (2020): 21-7.
  9. Calle EE., et al. “Body-mass index and mortality in a prospective cohort of U.S. adults”. N Engl J Med 341.15 (1999): 1097-105.
  10. Helvaci MR., et al. “Prevalence of white coat hypertension in underweight and overweight subjects”. Int Heart J 48.5 (2007): 605-13.
  11. Azadbakht L., et al. “Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome”. Diabetes Care 28.12 (2005): 2823-31.
  12. Helvaci MR., et al. “Body mass and blood pressure”. World Family Med 17.1 (2019): 36-40.
  13. Funahashi T., et al. “Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity”. Intern Med 38.2 (1999): 202-6.
  14. Fodor JG., et al. “Do we diagnose and treat coronary heart disease differently in men and women?”. Wien Med Wochenschr 154.17-18 (2004): 423-5.
  15. Grunberg NE., et al. “National working conference on smoking and body weight. Task Force 1: Mechanisms relevant to the relations between cigarette smoking and body weight”. Health Psychol 11 (1992): 4-9.
  16. Walker JF., et al. “The effect of smoking on energy expenditure and plasma catecholamine and nicotine levels during light physical activity”. Nicotine Tob Res 1.4 (1999): 365-70.
  17. Hughes JR and Hatsukami DK. “Effects of three doses of transdermal nicotine on post-cessation eating, hunger and weight”. J Subst Abuse 9 (1997): 151-9.
  18. Miyata G., et al. “Nicotine alters the usual reciprocity between meal size and meal number in female rat”. Physiol Behav 74.1-2 (2001): 169-76.
  19. Laaksonen M, Rahkonen O and Prattala R. “Smoking status and relative weight by educational level in Finland, 1978-1995”. Prev Med 27.3 (1998): 431-7.
  20. Froom P, Melamed S and Benbassat J. “Smoking cessation and weight gain”. J Fam Pract 46.6 (1998): 460-4.
  21. Helvaci MR, Kaya H and Gundogdu M. “Gender differences in coronary heart disease in Turkey”. Pak J Med Sci 28.1 (2012): 40-4.
  22. Prescott E., et al. “Smoking and risk of myocardial infarction in women and men: longitudinal population study”. BMJ 316.7137 (1998): 1043-7.
  23. Helvaci MR., et al. “Smoking may even cause irritable bowel syndrome”. World Family Med 17.3 (2019): 28-33.
  24. Helvaci MR, Kabay S, Gulcan E. “A physiologic events’ cascade, irritable bowel syndrome, may even terminate with urolithiasis”. J Health Sci 52.4 (2006): 478-81.
  25. Helvaci MR, Algin MC and Kaya H. “Irritable bowel syndrome and chronic gastritis, hemorrhoid, urolithiasis”. Eurasian J Med 41.3 (2009): 158-61.
  26. Rehm J. “Alcohol and mortality”. Alcohol Res 35.2 (2014): 174-83.
  27. Westman J., et al. “Mortality and life expectancy of people with alcohol use disorder in Denmark, Finland, and Sweden”. Acta Psychiatr Scand 131.4 (2015): 297-306.
  28. Roerecke M and Rehm J. “Alcohol use disorders and mortality: a systematic review and meta-analysis”. Addiction 108.9 (2013): 1562-78.
  29. Gabay C and Kushner I. “Acute-phase proteins and other systemic responses to inflammation”. N Engl J Med 340.6 (1999): 448-54.
  30. Wool GD and Reardon CA. “The influence of acute phase proteins on murine atherosclerosis”. Curr Drug Targets 8.11 (2007): 1203-14.
  31. Helvaci MR, Abyad A and Pocock L. “High and low density lipoproteins may be negative acute phase proteins of the metabolic syndrome”. Middle East J Nursing 14.1 (2020): 10-6.
  32. Pirillo A, Catapano AL and Norata GD. “HDL in infectious diseases and sepsis”. Handb Exp Pharmacol 224 (2015): 483-508.
  33. Ma C., et al. “Low-density lipoprotein cholesterol and risk of hemorrhagic stroke: a systematic review and dose-response meta-analysis of prospective studies”. Curr Atheroscler Rep 21.12 (2019): 52.
  34. Helvaci MR, Abyad A and Pocock L. “The safest values of low density lipoproteins in the plasma”. World Family Med 18.4 (2020): 18-24.
  35. Toth PP. “Cardiology patient page. The "good cholesterol": high-density lipoprotein”. Circulation 111.5 (2005): 89-91.
  36. Ertek S. “High-density lipoprotein (HDL) dysfunction and the future of HDL”. Curr Vasc Pharmacol 16.5 (2018): 490-8.
  37. Femlak M., et al. “The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk”. Lipids Health Dis 16.1 (2017): 207.
  38. Keene D., et al. “Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients”. BMJ 349 (2014): 4379.
  39. Helvaci MR, Abyad A and Pocock L. “What a low prevalence of diabetes mellitus between the most desired values of high density lipoproteins in the plasma”. World Family Med 18.7 (2020): 25-31.
  40. Helvaci MR., et al. “Positive and negative acute phase reactants in sickle cell diseases”. World Family Med 20.3 (2022): 36-42.
  41. Helvaci MR, Kaya H and Gundogdu M. “Association of increased triglyceride levels in metabolic syndrome with coronary artery disease”. Pak J Med Sci 26.3 (2010): 667-72.
  42. Helvaci MR., et al. “The safest value of plasma triglycerides”. World Family Med 17.7 (2019): 22-7.
  43. Helvaci MR, Abyad A and Pocock L. “The lowest is the safest value of plasma triglycerides”. World Family Med 17.10 (2019): 10-5.
  44. Helvaci MR, Abyad A and Pocock L. “The safest upper limit of triglycerides in the plasma”. World Family Med 18.1 (2020): 16-22.
  45. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 89.3 (1994): 1333-445.
  46. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO consultation (1999).
  47. Helvaci MR., et al. “Cholesterol may be a negative whereas triglycerides positive acute phase reactants in the plasma”. Asclepius Med Res Rev 4.1 (2021): 1-8.
  48. Helvaci MR., et al. “What is the relationship between hypertriglyceridemia and smoking?”. Middle East J Age and Ageing 8.6 (2011).